{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:43:53Z","timestamp":1794383033327,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:56:54Z","timestamp":1788879414000},"page":"446-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: A Large Prospective Cohort Study From the BioDay Registry"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-8003","authenticated-orcid":false,"given":"Nienke","family":"Veldhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselie E.","family":"Achten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7795-1043","authenticated-orcid":false,"given":"Chantal M.","family":"van Luijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P.A.","family":"Zuithoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coco","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlot M.","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor M.","family":"Dickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10247","key":"10.1016\/j.ajo.2026.09.003_bib0001","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0002","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.003_bib0003","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/all.70061","article-title":"Biologics to treat atopic dermatitis: effectiveness, safety, and future directions","volume":"81","author":"de Bruin-Weller","year":"2026","journal-title":"Allergy: Eur J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.003_bib0005","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/ICO.0000000000002866","article-title":"Prevalence and characteristics of Dupilumab-induced ocular surface disease in adults with atopic dermatitis","volume":"41","author":"Felfeli","year":"2022","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.003_bib0006","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/all.15717","article-title":"Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis","volume":"78","author":"Achten","year":"2023","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.003_bib0007","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bjd\/ljae344","article-title":"An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024","volume":"191","author":"Ardern-Jones","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.003_bib0008","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","article-title":"Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry","volume":"91","author":"Zhang","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.003_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"86","key":"10.1016\/j.ajo.2026.09.003_bib0010","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2021.09.029","article-title":"Dupilumab-induced ocular surface disease: a systematic review","volume":"2","author":"Fachler","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.003_bib0011","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","article-title":"Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis","volume":"160","author":"Boesjes","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.003_bib0013","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/01.ico.0000178741.14212.53","article-title":"Atopic ocular surface disease implications on tear function and ocular surface mucins","volume":"24","author":"Dogru","year":"2005","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.003_bib0014","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-associated mucin deficiency (DAMD)","volume":"9","author":"Barnett","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.003_bib0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/cea.14127","article-title":"Ocular surface disease is common in moderate-to-severe atopic dermatitis patients","volume":"52","author":"Achten","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/bjd\/ljad159","article-title":"Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay Registry","volume":"189","author":"Spekhorst","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ajo.2026.09.003_bib0018","unstructured":"OPIA Technologies S.A.S. EYEPRIMTM Handbook [Internet]. 2020. Available from: https:\/\/eyeprim.com\/shop\/wp-content\/uploads\/2020\/01\/Handbook-20200129-final.pdf."},{"key":"10.1016\/j.ajo.2026.09.003_bib0019","series-title":"Series in Probability and Statistics","first-page":"353","article-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2011"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.003_bib0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.003_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.003_bib0022","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","article-title":"Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases","volume":"20","author":"Beck","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.003_bib0023","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjd.20706","article-title":"New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab","volume":"186","author":"Bortoluzzi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12386","article-title":"Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: a daily practice analysis","volume":"14","author":"Schl\u00f6sser","year":"2024","journal-title":"Clin Transl Allergy"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.003_bib0025","first-page":"3277","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye (Basingstoke)"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.003_bib0026","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/all.15326","article-title":"IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro","volume":"77","author":"Hansen","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.003_bib0027","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0161-6420(98)98032-0","article-title":"Impression cytology in atopic dermatitis","volume":"105","author":"Dogru","year":"1998","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.003_bib0028","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jtos.2012.05.001","article-title":"Goblet cells of the normal human bulbar conjunctiva and their assessment by impression cytology sampling","volume":"10","author":"Doughty","year":"2012","journal-title":"Ocul Surf"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:03:44Z","timestamp":1794301424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426005088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S0002939426005088"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.003","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: A Large Prospective Cohort Study From the BioDay Registry","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}